Michael Halpin
Chief Operating Officer bei VERICEL CORPORATION
Vermögen: 49 367 $ am 31.03.2024
Profil
Michael Halpin is currently the Chief Operating Officer at Vericel Corp.
Prior to his current position, he held the role of Vice President-North American Region Regulatory at Genzyme Corp.
from 2002 to 2017.
He also worked as Vice President-North American Region Regulatory at Sanofi Corp.
Mr. Halpin completed his undergraduate and graduate degrees at the University of Virginia.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
VERICEL CORPORATION
0,00% | 11.03.2024 | 949 ( 0,00% ) | 49 367 $ | 31.03.2024 |
Aktive Positionen von Michael Halpin
| Unternehmen | Position | Beginn |
|---|---|---|
| VERICEL CORPORATION | Chief Operating Officer | 15.06.2019 |
Ehemalige bekannte Positionen von Michael Halpin
| Unternehmen | Position | Ende |
|---|---|---|
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | General Counsel | - |
| Sanofi Corp. | Corporate Officer/Principal | - |
Ausbildung von Michael Halpin
| University of Virginia | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| VERICEL CORPORATION | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
| Sanofi Corp. |
